Warfarin pharmacogenetics meets clinical use

Blood

Volumn 118, Issue 11, 2011, Pages 2938-2939

  Schwab, Matthias ^a   Schaeffeler, Elke ^a  

^a Dr Margarete Fischer Bosch Institute of Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; APOLIPOPROTEIN E; CYTOCHROME P450; CYTOCHROME P450 2C18; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; DABIGATRAN; OXIDOREDUCTASE; PROTEIN C; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ANTICOAGULANT THERAPY; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOTE; PHARMACODYNAMICS; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; STROKE; VENOUS THROMBOEMBOLISM;

EID: 80052954066     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-367763     Document Type: Note

References (10)

1. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood. 2011;118(11):3163-3171.
2. Green ED, Guyer MS, National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470(7333):204-213.
3. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007;9(10):665-674.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
5. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147(11):755-765. (Pubitemid 351664440)
6. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci. 2009;30:375-386.
7. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433.
8. Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet. 2010;19(23):4735-4744.
9. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet. 2008;82(2):495-500.
10. Auffray C, Caulfield T, Khoury MJ, Lupski JR, Schwab M, Veenstra T. Genome Medicine: past, present and future. Genome Med. 2011;3(1):6.